ArticleFrontiers in immunology2026
Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
- Liquid Biopsy in Colorectal Cancer: Future Perspectives Through the Lens of Artificial Intelligence-A Comprehensive Review of Novel Literature.International journal of molecular sciences · 2026Review
- How advances in machine learning drive early detection and risk prediction of early-onset colorectal cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately detect CRC. Methods: 573 individuals from Sir Run Run Shaw Hospital, two community healthcare centers and three additional medical centers, were collected between April 1, 2023, and December 12, 2025. Participants were divided into training, internal validation, and external validation cohorts. A variety of cfDNA fragmentomic features were analyzed and incorporated into machine learning models. The models were evaluated using 10-fold cross-validation and assessed for accuracy, sensitivity, specificity, and AUC values. We also performed differential analysis of key genomic features, such as Results: The machine learning algorithm demonstrated robust discriminative performance across all datasets using generalized linear modeling (GLM), achieving AUC values of 0.959 (training set), 0.979 (internal validation cohort), and 0.959 (external validation cohort). Notably, the model exhibited particularly strong classification accuracy for advanced-stage colorectal cancer (CRC). Comparative cfDNA profiling revealed distinct molecular signatures between benign and malignant samples: benign samples were characterized by elevated frequencies of Conclusion: This study demonstrates that cfDNA fragmentomic profiling, particularly differential patterns of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.